Clinical outcome with enalapril in symptomatic chronic heart failure; a dose comparison
Author(s) -
P A Poole-Wilson,
J Cleland,
W. B. Hubbard,
George C. Sutton,
J Pittard,
Cynthia R. Osborne,
Clarine Long,
S Ingham,
Paul Robinson,
S Ball,
J R Hampton,
Neil R Poulter,
GeorgeR. Murray,
Christopher Travill,
RJ Bain,
A Baksi,
R. D. Baxter,
Agaath Been,
KE Berkin,
Rachel Blackwood,
RL Blandford,
RM Boyle,
Maurice Buchalter,
R Campbell,
No Value Challenor,
Barbara Cheadle,
Andrew J.S. Coats,
P Collins,
Campbell Cowan,
John Creamer,
C.M. Dancy,
J Davies,
Rosemary C. Davies,
M Ehsanulliah,
Andrew Elder,
J. Fowler,
RA Fulcher,
MK Ghosh,
R. S. Greenbaum,
TW Greenwood,
S.F.M. Grimmer,
James E. Harvey,
Allen H. Heller,
A. Henderson,
T. Hendra,
WG Hendrey,
Jonathan J. Hogan,
K. Hollinrake,
P.J.A. HOLT,
Jenny Hutton
Publication year - 1998
Publication title -
european heart journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 4.336
H-Index - 293
eISSN - 1522-9645
pISSN - 0195-668X
DOI - 10.1053/euhj.1997.0839
Subject(s) - medicine , heart failure , enalapril , clinical endpoint , angiotensin converting enzyme , incidence (geometry) , ace inhibitor , cardiology , randomized controlled trial , blood pressure , physics , optics
Angiotensin converting-enzyme (ACE) inhibitors used for the treatment of heart failure relieve symptoms, increase exercise performance, reduce hospital admissions and prolong life. The large survival studies have used higher doses of ACE inhibitors than those commonly used in clinical practice. NETWORK was set up to compare the effect of dose on the clinical outcome of ACE inhibition.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom